VYGR News and Press, Voyager Therapeutics Inc.

LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) poster presentation at the upcoming Alzheimer's Association I...

LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, will participate i...

2026-06-10 15:19:18 ET More on Eli Lilly Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Eli Lilly: Bears Are Missing The Underlying Thesis Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual St...

- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular t...

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a b...

2026-05-07 17:05:58 ET More on Voyager Therapeutics Voyager Therapeutics, Inc. (VYGR) Discusses Tracer AAV Capsid Platform for Enhanced CNS Gene Therapy Delivery Transcript Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026 Voyager Ther...

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - - Ended Q1 2026 with cash position of $172 million, runway into 2028 - LEXINGTON, Mass....

2026-05-07 12:54:48 ET More on Neurocrine Biosciences Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside Neurocrine Biosciences, Inc. (NBIX) Q1 2026 Earnings Call Transcript Neurocrine Biosciences, Inc. 2026 Q1 - Results - Earnings Call Pre...

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs - - Additional data demonstrate continued capsid innovation via muscular and neuromuscular targeting, im...

2026-04-21 16:56:37 ET More on Voyager Therapeutics Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026 Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript Voyager Therapeutics, Inc. (VYGR) Presents at ...